Navigation Links
CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
Date:6/4/2013

KING OF PRUSSIA, Pa., June 4, 2013 /PRNewswire/ -- CSL Behring has dosed the first patient in Part 3 of its AFFINITY clinical trial program, which is now in phase III. AFFINITY is an open-label, non-randomized, multi-center study evaluating the efficacy, safety and pharmacokinetics of its novel investigational recombinant coagulation single-chain factor VIII (rVIII-SingleChain) for the treatment of hemophilia A. The patient was dosed in Vienna, Austria and had a successful major surgery.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

The CSL Behring rVIII-SingleChain is a novel recombinant single-chain Factor VIII design that uses a strong, covalent bond that has been shown to improve the stability and half-life of factor VIII (FVIII). A recombinant factor therapy option with a longer half-life could provide a longer dosing interval, leading to less frequent injections. This may have the potential to improve compliance and ease prophylaxis, improving the quality of life for people with hemophilia A.

"We are proud and excited that this recombinant coagulation factor development program is progressing into Phase III clinical studies and look forward to sharing the clinical trial results for our novel rVIII-SingleChain molecule with the hemophilia community in the future," said Russell Basser , M.D., CSL Senior Vice President, Global Clinical Research & Development. "As part of our ongoing commitment to the hemophilia community, we are developing and investigating innovative recombinant factor therapies for the treatment of both hemophilia A and B that have the potential to offer patients and caregivers significant advances in treatment and convenience of factor infusion." CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL), is developing rVIII-SingleChain through the AFFINITY clinical trial program.

About the AFFINITY Phase I/III Study 
The Phase I/III study is an open-label, multi-center trial that examines the crossover safety, efficacy and pharmacokinetics of recombinant coagulation single-chain factor VIII compared with recombinant human antihemophilic factor VIII (octocog alpha). 

In Part 1 of the study, 27 subjects received a single infusion of 50 IU/kg body weight (b.w.) of octocog alfa followed by a single infusion of 50 IU/kg b.w. rVIII-SingleChain. Results of Part 1 of the study will be presented at the 2013 International Society on Thrombosis and Haemostasis in Amsterdam, Netherlands on 2 July. In Parts 2 and 3 of the study, subjects will receive infusions of rVIII-SingleChain to prevent and treat bleeding (if required), at a dose and frequency determined by their study doctor (based on the subject's underlying bleeding phenotype). More information about the study design can be found at www.clinicaltrials.gov

Recombinant FVIII molecules so far available consist of a heavy and a light chain. Under certain conditions, these chains can dissociate, resulting in the formation of separated, or "dissociated," rFVIII chains that are not hemostatically active. The CSL Behring rVIII-SingleChain uses a strong, covalent bond that connects the light and heavy chains, thereby creating a stable single chain rFVIII.

In-house studies have shown that the molecular integrity of rVIII-SingleChain is significantly increased using the single-chain design, resulting in a homogenous product that is more stable than currently available FVIII products. In addition, in-vitro studies have shown that rVIII-SingleChain demonstrates a strong affinity for von Willebrand factor (VWF), resulting in a faster and more efficient binding to VWF. The FVIII/VWF complex plays an important role in the physiological activity and clearance of FVIII and has been shown to have an influence on the presentation of FVIII to the immune system.

The research leading to the initiation of the studies that CSL Behring is now conducting is the result of collaboration across the CSL Behring research sites in Marburg, Germany, in King of Prussia, USA, and at laboratories operated by CSL Limited in Melbourne, Australia.

About Hemophilia
Hemophilia is a congenital bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. In nearly all cases, it affects only males. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX (FIX). The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient- or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit http://www.cslbehring.com/.

Media Contact:

Sheila Burke
Director, Public Relations & Communications
Worldwide Commercial Operations
1 610-878-4209


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
2. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
3. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
4. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
5. Summit Yields One-of-a-Kind Opportunity To Reduce Prescription Drug Overdoses
6. CLAAD Warns of Increase in Prescription Drug Overdoses
7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
8. As Prescription Painkiller Overdoses Mount, Researchers Outline Effective Approaches to Curb Epidemic
9. DebMed to Display Clients Increased Hand Hygiene Compliance Rates and Worlds First Monitored Point-of-Care Dispenser at APIC
10. Cochlear Americas Receives FDA Approval for the First and Only Ear Level Accessory for Waterproof Hearing with Cochlear Implants
11. MEDIFIRST SOLUTIONS, INC. To Exhibit At The Orlando International Beauty Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
(Date:5/23/2016)... , May 23, 2016 ... Size, Share, Development, Growth and Demand Forecast to ... and Other), by Application (Drug Discovery and Development, ... Users (Pharmaceuticals, Life Science and Biotechnology, Academic and ... Market Research, the global mass spectrometry market ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... WaterAid launched the #perioddrama campaign to mark Menstrual ... 1 billion women around the world who do not have access to a toilet, even ... US about their dread of #perioddrama. The (sometimes hilarious) results help shine a light on ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local chiropractor Dr. Jason ... 21, 2016. Dr. Gerard, who holds a Doctorate of Chiropractic and Bachelors of ... health and wellness in Third World countries where resources are limited. , ChiroMission ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Dream Builders Project, ... and other necessities to Eunime Orphanage in Tijuana, Mexico on Saturday, May 21st. The ... at Peter Piper Pizza. , More than 15 volunteers traveled from Los Angeles ...
(Date:5/24/2016)... ... 2016 , ... The old expression “a pain in the neck” takes on ... misunderstood, whiplash should be swiftly diagnosed and treated if those affected want to quickly ... Spine Center . , So named because of the whip-like, rapid back-and-forth neck ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... After graduating ... He spent the next decade in hospitals, on medication, living on Social Security disability ... at the Illness and How I Beat It!” (published by Balboa Press), Alexander shares ...
Breaking Medicine News(10 mins):